iStock Rating

Press Releases
OXiGENE Reports First Quarter 2013 Financial Results
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial
OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast
OXiGENE Announces $5 Million Private Placement
Free Research Reports on HBIO, KIOR, NIHD and OXGN Issued by the Paragon Report
OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents
OXiGENE Reports Full Year 2012 Financial Results
OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast
Free Research Reports on ATML, GMCR, OXGN and TDC Issued by the Bedford Report
Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial
OXiGENE Announces Presentation at BIO CEO Conference on February 12th
OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors
OXiGENE Regains Nasdaq Closing Bid Price Compliance
The Real Story Behind OXGN, AAMC, BLKB and ROYL
OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
Free Research Reports on AKS, CLNE, OXGN and ZAZA Issued by the Bedford Report
OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting
OXiGENE Reports Third Quarter 2012 Financial Results
OXiGENE Announces Presentation at BIO-Europe Conference on November 14th
OXiGENE Announces Third Quarter 2012 Earnings Conference Call and Webcast
OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT(R) in Anaplastic Thyroid Cancer
OXiGENE to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat(R) in Anaplastic Thyroid Cancer
OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta A/S
OXiGENE Reports Second Quarter 2012 Financial Results
OXiGENE Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus Bevacizumab Achieves Important Interim Safety Objective
OXiGENE Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule
OXiGENE In-Licenses Rights to Promising Program for Neuroendocrine Tumors
OXiGENE Announces Publication of Key Data Showing Antitumor Activity of ZYBRESTAT(R) Combined With Bevacizumab
OXiGENE Announces First Quarter 2012 Earnings Conference Call and Webcast
OXiGENE Reports Data Showing Median Survival and One-Year Survival Improvement in Anaplastic Thyroid Cancer Patients Treated With ZYBRESTAT(R) and Chemotherapy
OXiGENE Reports Full Year 2011 Financial Results
OXiGENE Announces Full Year 2011 Earnings Conference Call and Webcast
Biotech Sector Shows No Signs of Slowing -- OXiGENE and Generex Poised for Growth
OXiGENE to Present at BIO CEO & Investor Conference
OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use Basis
OXiGENE Presents Data From FAVOR Study of ZYBRESTAT in PCV
OXiGENE Announces Purchase Agreement for Up to $20 Million With Lincoln Park Capital
OXiGENE Reports Third Quarter 2011 Financial Results
OXiGENE Reports Final Data From Phase 2 FALCON Study of ZYBRESTAT in Non-Small Cell Lung Cancer
OXiGENE Announces Third Quarter 2011 Earnings Conference Call and Webcast
OXiGENE and Neoprobe Reawaken Investor Interest in Biotechnology Industry
OXiGENE Presents Data Confirming Survival Benefit of ZYBRESTAT in Patients With Anaplastic Thyroid Cancer
OXiGENE Announces Changes to Board of Directors
OXiGENE to Present Additional ZYBRESTAT(TM) Survival Data at European Thyroid Association Annual Meeting
Marina Biotech and OXiGENE Attack Cancer From Different Angles
OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs
OXiGENE Reports Second Quarter 2011 Financial Results
Ariad and OXiGENE Show Encouraging Growth Potential
ZYBRESTAT(TM) Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer
OXiGENE Complies With NASDAQ Listing Requirements
OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer
OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO
OXiGENE Reports First Quarter 2011 Financial Results
OXiGENE Announces Initiation of Phase 1 Trial of OXi4503 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Global Conditions to Influence Pharmaceuticals -- Industry Report Featuring OXiGENE and Merck & Co., Inc.
Sequenom and OXiGENE Optimistic About Future Growth Prospects
OXiGENE Announces First Quarter 2011 Earnings Conference Call and Webcast
OXiGENE Announces First Patient Enrolled in Phase 2 Study of ZYBRESTAT in Patients With Ovarian Cancer
OXiGENE Receives Meeting Minutes from FDA Type C Meeting on ZYBRESTAT(TM) Anaplastic Thyroid Program
OXiGENE to Collaborate With NCI/CTEP, GOG on Phase 2 Study of ZYBRESTAT in Patients With Relapsed Ovarian Cancer
OXiGENE to Present at BIO CEO and Investor Conference on February 14, 2011
OXiGENE Enters Into Exchange Agreements With Warrant Holders
OXiGENE Reports Further Positive Safety and Efficacy Data From Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer
OXiGENE Reports Third Quarter 2010 Financial Results
OXiGENE Awarded $733K in Tax Credit Grants
OXiGENE Announces Third Quarter 2010 Earnings Conference Call and Webcast
Ongoing Analyses of Randomized Phase 2/3 ATC Data, Including Subgroup Analyses, Continue to Show ZYBRESTAT(TM) (CA4P) Improves Overall Survival in Patients With Anaplastic Thyroid Cancer (ATC)
ZYBRESTAT(TM) (CA4P) Improves Overall Survival in a Phase 2/3 Trial (FACT Study) of Patients With Anaplastic Thyroid Cancer (ATC)
OXiGENE Reports Second Quarter 2010 Financial Results